Skip to main content

Arcus Biosciences, Inc.

RCUS
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001724521

In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 2 sales; 231 institutions reported holding it in 13F filings for Q2 2026, worth $3.78B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Arcus Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
2 filings
2 insiders, $2.12M in total
Insiders trading
2
Net value
−$2.12M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Arcus Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Arcus Biosciences, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Azoy AlexanderChief Accounting Officer39,581Aug 24, 20266
Jaen Juan C.President822,240IndirectJul 13, 20269
Perlman Andrew JDirector48,325Jun 12, 20261
Falberg Kathryn EDirector44,300Jun 12, 20261
Kaneko YasunoriDirector25,700Jun 12, 20261
Machado PatrickDirector44,300Jun 12, 20261
Lacey David L.Director76,652Jun 12, 20261
Lambert NicoleDirector43,000Jun 12, 20261
Ribas AntoniDirector44,300Jun 12, 20262
Tang Carolyn C.General Counsel184,607Jun 12, 20263
Goeltz II Robert C.Chief Financial Officer84,161May 12, 20266
Rosen Terry JChief Executive Officer2,236,409Jan 26, 20264
Jarrett JenniferChief Operating Officer224,024Jan 26, 20264
Markus RichardChief Medical Officer89,647Jan 26, 20262
Gilead Sciences, Inc.10% Owner31,424,760Feb 20, 20250
Nuyten Dimitry SAChief Medical Officer87,518Dec 17, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 24, 2026 (view filing)5:52 PM ETAug 213 daysAzoy AlexanderChief Accounting OfficerSSale−2.83K$30.00−$84.8K−6.7%39.6K after10b5-1
Jul 13, 2026 (view filing)5:36 PM ETJul 9-104 daysJaen Juan C.PresidentSSale−68.6K$29.63−$2.03M−7.7%822.2K after3 lots10b5-1
Jun 24, 2026 (view filing)Jun 22-242 daysJaen Juan C.PresidentSSale−31.4K$27.92−$877.5K−3.4%890.8K after4 lots10b5-1
Jun 1, 2026 (view filing)Jun 1Same dayAzoy AlexanderChief Accounting OfficerSSale−2.56K$25.77−$66.0K−6.1%39.6K after10b5-1
May 12, 2026 (view filing)May 111 dayGoeltz II Robert C.Chief Financial OfficerSSale−7.76K$25.63−$199.0K−8.4%84.2K after10b5-1
Jan 7, 2026 (view filing)Jan 52 daysJaen Juan C.PresidentSSale−31.8K$21.41−$681.3K−3.3%922.2K after3 lots10b5-1
Jan 2, 2026 (view filing)Dec 31, 20252 daysGoeltz II Robert C.Chief Financial OfficerSSale−6.55K$23.38−$153.2K−8.8%67.9K after10b5-1
Dec 18, 2025 (view filing)Dec 16-172 daysMarkus RichardChief Medical OfficerSSale−9.55K$22.01−$210.1K−12.7%65.6K after2 lots10b5-1
Dec 18, 2025 (view filing)Dec 16-172 daysTang Carolyn C.General CounselSSale−14.5K$22.01−$318.5K−10.4%124.7K after2 lots10b5-1
Dec 18, 2025 (view filing)Dec 16-182 daysAzoy AlexanderChief Accounting OfficerSSale−8.83K$22.13−$195.4K−32.3%18.5K after3 lots10b5-1
Dec 18, 2025 (view filing)Dec 16-172 daysJarrett JenniferChief Operating OfficerSSale−21.2K$22.01−$466.8K−9.9%193.0K after2 lots10b5-1
Dec 18, 2025 (view filing)Dec 16-172 daysGoeltz II Robert C.Chief Financial OfficerSSale−12.7K$22.01−$278.7K−14.5%74.5K after2 lots10b5-1
Dec 18, 2025 (view filing)Dec 16-172 daysJaen Juan C.PresidentSSale−21.2K$22.01−$466.8K−5.8%346.0K after2 lots10b5-1
Dec 18, 2025 (view filing)Dec 16-172 daysRosen Terry JChief Executive OfficerSSale−54.7K$22.01−$1.20M−2.4%2.19M after2 lots10b5-1
Dec 5, 2025 (view filing)Dec 41 dayJaen Juan C.PresidentSSale−83.0K$24.71−$2.05M−8.0%954.1K after10b5-1
Dec 1, 2025 (view filing)Nov 265 daysAzoy AlexanderChief Accounting OfficerSSale−1.90K$26.00−$49.4K−6.5%27.4K after10b5-1
Nov 26, 2025 (view filing)Nov 26Same dayGoeltz II Robert C.Chief Financial OfficerSSale−5.00K$25.00−$125.0K−5.4%87.1K after10b5-1
Nov 19, 2025 (view filing)Nov 17-182 daysJaen Juan C.PresidentSSale−50.0K$20.26−$1.01M−4.6%1.04M after3 lots10b5-1
Nov 12, 2025 (view filing)Nov 75 daysJarrett JenniferChief Operating OfficerSSale−50.3K$18.97−$954.0K−19.0%214.2K after10b5-1
Nov 3, 2025 (view filing)Oct 304 daysJaen Juan C.PresidentSSale−4.31K$20.32−$87.7K−0.4%1.09M after10b5-1
Oct 30, 2025 (view filing)Oct 28-292 daysJaen Juan C.PresidentSSale−96.9K$20.76−$2.01M−8.2%1.09M after4 lots10b5-1
Oct 29, 2025 (view filing)Oct 281 dayGoeltz II Robert C.Chief Financial OfficerSSale−5.00K$20.00−$100.0K−5.1%92.1K after10b5-1
Oct 8, 2025 (view filing)Oct 6-82 daysJarrett JenniferChief Operating OfficerSSale−50.3K$14.92−$750.5K−19.0%214.2K after2 lots10b5-1
Sep 30, 2025 (view filing)Sep 291 dayAzoy AlexanderChief Accounting OfficerSSale−2.83K$13.00−$36.8K−9.4%27.4K after10b5-1
Sep 5, 2025 (view filing)Sep 5Same dayAzoy AlexanderChief Accounting OfficerSSale−1.58K$11.88−$18.8K−5.0%30.2K after10b5-1
Feb 27, 2025 (view filing)Feb 27Same dayKaneko YasunoriDirectorPPurchase+20.0K$10.06+$201.2K+238.1%28.4K after
Feb 27, 2025 (view filing)Feb 27Same dayRosen Terry JChief Executive OfficerPPurchase+19.8K$10.18+$201.6K+0.8%2.55M after
Feb 20, 2025 (view filing)Feb 182 daysGilead Sciences, Inc.10% OwnerPPurchase+1.36M$11.00+$15.0M+4.5%31.4M after
Jan 3, 2025 (view filing)Dec 31, 20243 daysGoeltz II Robert C.Chief Financial OfficerSSale−3.59K$15.00−$53.9K−5.6%60.1K after10b5-1
Dec 4, 2024 (view filing)Dec 22 daysAzoy AlexanderChief Accounting OfficerSSale−201$15.32−$3.08K−1.0%19.1K after10b5-1
Aug 15, 2024 (view filing)Aug 132 daysAzoy AlexanderChief Accounting OfficerSSale−1.36K$14.97−$20.3K−6.6%19.1K after10b5-1
Mar 29, 2024 (view filing)Mar 272 daysJarrett JenniferChief Operating OfficerSSale−11.6K$17.55−$202.7K−5.1%215.3K after10b5-1
Mar 20, 2024 (view filing)Mar 182 daysJarrett JenniferChief Operating OfficerSSale−13.4K$17.92−$240.9K−5.6%226.8K after2 lots10b5-1
Feb 28, 2024 (view filing)Feb 26-272 daysJarrett JenniferChief Operating OfficerSSale−58.6K$20.09−$1.18M−19.6%240.3K after2 lots10b5-1
Feb 28, 2024 (view filing)Feb 26-272 daysJaen Juan C.PresidentSSale−27.0K$20.09−$543.2K−2.2%1.19M after2 lots10b5-1
Jan 31, 2024 (view filing)Jan 292 daysGilead Sciences, Inc.10% OwnerPPurchase+15.2M$21.00+$320.0M+102.8%30.1M after
Jan 4, 2024 (view filing)Jan 22 daysGoeltz II Robert C.Chief Financial OfficerSSale−2.00K$20.00−$40.1K−3.7%51.8K after10b5-1
Jan 4, 2024 (view filing)Jan 22 daysJaen Juan C.PresidentSSale−6.97K$20.09−$140.1K−0.6%1.22M after10b5-1
Dec 26, 2023 (view filing)Dec 224 daysJarrett JenniferChief Operating OfficerSSale−21.5K$17.76−$382.2K−7.7%258.9K after10b5-1
Dec 5, 2023 (view filing)Dec 14 daysAzoy AlexanderChief Accounting OfficerSSale−282$14.95−$4.22K−2.4%11.6K after10b5-1
Sep 26, 2023 (view filing)Sep 224 daysJarrett JenniferChief Operating OfficerSSale−21.4K$19.99−$427.2K−6.6%302.7K after10b5-1
Jul 31, 2023 (view filing)Jul 283 daysJarrett JenniferChief Operating OfficerSSale−45.0K$20.25−$911.3K−11.8%336.6K after10b5-1
Jul 5, 2023 (view filing)Jul 32 daysAzoy AlexanderChief Accounting OfficerSSale−1.02K$20.41−$20.8K−8.1%11.6K after10b5-1
Jun 30, 2023 (view filing)Jun 282 daysGilead Sciences, Inc.10% OwnerPPurchase+1.01M$19.26+$19.5M+7.3%14.8M after
Jun 26, 2023 (view filing)Jun 224 daysJarrett JenniferChief Operating OfficerSSale−12.4K$19.12−$237.8K−3.2%381.6K after10b5-1
Jun 16, 2023 (view filing)Jun 16Same dayJarrett JenniferChief Operating OfficerSSale−12.6K$19.35−$243.1K−3.1%394.0K after10b5-1
Jun 9, 2023 (view filing)Jun 72 daysGoeltz II Robert C.Chief Financial OfficerSSale−4.05K$20.04−$81.1K−6.4%59.4K after10b5-1
Mar 20, 2023 (view filing)Mar 164 daysJarrett JenniferChief Operating OfficerSSale−8.73K$16.81−$146.7K−2.1%406.2K after
Jan 30, 2023 (view filing)Jan 26-274 daysJarrett JenniferChief Operating OfficerSSale−1.90K$23.53−$44.7K−0.5%414.9K after2 lots
Dec 16, 2022 (view filing)Dec 16Same dayGoeltz II Robert C.Chief Financial OfficerSSale−2.45K$30.75−$75.4K−17.5%11.6K after2 lots